Biotech ETF Nears a Buy Point

Biotechnology exchange traded funds have rebounded from their March/April swoons, recapturing significant portions of the losses incurred during the momentum sell-off. Even with that, some investors remain reluctant to embrace biotech ETFs as evidenced by the fact that since the start of the third...